Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreatic Diseases Clear all
Completed Phase 2 Interventional Results available

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

NCT00865904
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
321
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 244 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies

NCT01401907
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer, Gastric Cancer, Liver Cancer, Pancreatic Cancer
Interventions
early palliative care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 1 Interventional

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT01413087
View directory record Official record
Conditions
Pancreas, Adenocarcinoma
Interventions
Biological/Vaccine: BC-819
Biological
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Mineola, New York • Philadelphia, Pennsylvania • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 23, 2026, 2:21 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Not listed Phase 3 Interventional

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

NCT00005871
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional

Cinacalcet to Treat Familial Primary Hyperparathyroidism

NCT00325104
View directory record Official record
Conditions
Hypercalcemia, Familial Primary Hyperparathyroidism
Interventions
Parathyroid hormone testing, Serum calcium testing
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Markers of Early Pancreas Cancer

NCT03568630
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

NCT07223047
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

NCT02983578
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency, Refractory Colorectal Carcinoma, Refractory Lung Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Danvatirsen, Durvalumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

NCT03126435
View directory record Official record
Conditions
Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
EndoTAG-1, Gemcitabine
Drug
Lead sponsor
SynCore Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 1 Interventional

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

NCT00593008
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Temsirolimus, Gemcitabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493
View directory record Official record
Conditions
Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
AZD5863
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Not listed Not applicable Interventional

Fine Needle Biopsy of Solid Pancreatic Mass Lesions

NCT04085055
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Solid pancreatic mass lesion biopsy
Diagnostic Test
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

NCT00841035
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 23, 2026, 2:21 PM EDT
Terminated Phase 1 Interventional

CAR T Cell Immunotherapy for Pancreatic Cancer

NCT03323944
View directory record Official record
Conditions
Pancreatic Cancer, Cancer of the Pancreas
Interventions
huCART-meso cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

NCT00028834
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 23, 2026, 2:21 PM EDT
No Longer Available No phase listed Expanded access

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

NCT01980732
View directory record Official record
Conditions
Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors
Interventions
68Ga-DOTA TATE
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms

NCT05225038
View directory record Official record
Conditions
Pancreatic Neoplasms, Periampullary Carcinoma
Interventions
Exercise, Nutritional, Behavioral Medicine, Smoking Cessation
Other · Dietary Supplement · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 2:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ghrelin Levels in Pancreatic Cancer Patients

NCT00225745
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Blood draw
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 23, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System

NCT03674281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Cognitive Change
Interventions
SAP, CLC
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 23, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

NCT06411795
View directory record Official record
Conditions
Duodenal Neoplasm, Pancreatic Neoplasm
Interventions
Bupivacaine, Hydromorphone, Iopamidol, Liposomal Bupivacaine, Medical Chart Review, Questionnaire Administration, Thoracic Epidural Analgesia, Ultrasound Imaging, X-Ray Imaging
Drug · Other · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 23, 2026, 2:21 PM EDT